Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn(Heidelberg University), Wilfried Eberhardt(National Center for Tumor Diseases)
Cited by 872
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k